Global Humanized Liver Mice Models Industry Market Research 2022-2030
Product Code: RP-ID-10151804 |
Published Date: 21 Oct 2022 |
Region: Global |
Category: Healthcare & Pharmaceuticals |
Report ID: 10151804
Market Overview:
Global Humanized Liver Mice Models Industry Market Research 2022-2030
"In 2021, the global humanized liver mouse model market is anticipated to expand at a CAGR of ~6% over the forecast period 2022-2030. As a promising alternative to traditional animal models. The human liver is a reservoir of several important pathogens, causing more than 500 million infections and 2.5 to 4.5 million deaths each year.
Humanized liver mouse model market at global and regional levels. The report provides an in-depth analysis of the humanized liver mouse model market from 2019 to 2026, with 2019 as the base year and 2020 to 2026 as the forecast period. The 2016-2018 data has been included as historical information.
The study provides a detailed view on market growth throughout the forecast period mentioned above, in terms of revenue estimates (in millions of dollars), in different regions, including North America (NA), Europe (EU), Asia Pacific (APAC), Middle East and Africa (MEA) and South America This report provides qualitative and quantitative information about the trends in the humanized liver mouse model industry, and detailed analysis of the market size and growth rate of all market segments. The global humanized liver mouse model market is segmented by application and region.
Global humanized liver mouse model market dynamics:
The increase in government funding for liver disease treatments increases the number of R&D activities that will drive the global market during the forecast period. They are more powerful tools and have sparked interest in using them as models to answer other questions specific to the liver. Many new genome editing therapies are being developed, among which humanized liver mice provide a unique testing environment for genome editing therapy delivery methods, showing huge market opportunities. Humanized transgenic mice are valuable animal models for understanding the importance of specific human drug-metabolizing enzymes in drug clearance and pharmacokinetics, as well as predicting potential drug-drug interactions and chemical toxicity in humans. The efficacy, toxicology and pharmacokinetic characteristics of candidate drugs for small molecule drugs and biological agents, including host-directed antibodies and pathogenic components. Preclinical evaluation of the efficacy of vaccines in mice transplanted with human tissues can effectively support various pathologies, as well as research on the safety, effectiveness and pharmacokinetics of therapeutic drugs and biological products.
The characteristics of drug metabolism show that the human liver mouse model has shown useful results in predicting human drug interactions and the induction and inhibition of endogenous enzymes. All these reasons provide a global basis for the development of drugs marketed by humanized liver mouse models. Growth opportunities. For example, mice with a human immune system and supplemented human lung tissue can mimic the pathogenesis of tuberculosis or cytomegalovirus (CMV).
Regional insight :
Into the global humanized liver mouse model market: The implementation of high research facilities and research facilities in research institutions, especially in the field of life sciences, is expected to expand the global market for humanized liver mouse models. The humanized liver mouse model develops the global market in European economies. The development of a new genetically modified human liver model with advanced technology is a key development and has a positive impact on the global humanized liver mouse model.
Major players:
In the global humanized liver mouse model market • Jackson Laboratory • Crown Bioscience Inc. • Charles River Laboratories International Inc. • Taconic Biosciences Inc. • Ingenious Targeting Laboratory Inc. • Trans Genic Inc. Ltd. • GenOway • Creative Animodel • Horizon Exploration Group Co., Ltd. • Hera BioLabs • PhoenixBio Group • Beijing Vinda Biotechnology Co., Ltd. • Yecuris Corporation"
Related Reports
Study Period : 2023-2035
Report Format : PDF,PPT
Delivery Timeline : 48-72 Business Hours
Proof of Quality & Reliability
